Novartis' Sjögren's Disease Drug Shows Sustained Improvement in Extension Study

11:32 PM EST, 11/10/2026 (MT Newswires) -- Swiss drugmaker Novartis' (NOVN.SW) fully human monoclonal antibody ianalumab continued to improve systemic disease activity in patients with Sjögren's disease during the ongoing Neptunus extension study. Long-term trial data showed further reductions in systemic disease activity between week 48 and week 108 among patients receiving monthly 300-milligram doses of ianalumab. Improvements in physician- and patient-reported outcomes and salivary flow were also maintained, according to a Tuesday release. Ianalumab is under regulatory review in several countries, with a decision from the US Food and Drug Administration expected in 2026.